Skip to main content
Top
Published in: Current Rheumatology Reports 5/2016

01-05-2016 | Pediatric Rheumatology (S Ozen, Section Editor)

Pediatric Mixed Connective Tissue Disease

Authors: Roberta A. Berard, Ronald M. Laxer

Published in: Current Rheumatology Reports | Issue 5/2016

Login to get access

Abstract

Pediatric-onset mixed connective tissue disease is among the rare disease entities in pediatric rheumatology and includes features of arthritis, polymyositis/dermatomyositis, systemic lupus erythematosus, and systemic sclerosis. Accurate recognition and diagnosis of the disease is paramount to prevent long-term morbidity. Advances in the genetic and immunologic understanding of the factors involved in the etiopathogenesis provide an opportunity for improvements in prognostication and targeted therapy. The development of a multinational cohort of patients with mixed connective tissue disease would be invaluable to provide more updated data regarding the clinical presentation, to develop a standardized treatment approach, disease activity and outcome tools, and to provide data on long-term outcomes and comorbidities.
Literature
1.
go back to reference Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52:148–59.CrossRefPubMed Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med. 1972;52:148–59.CrossRefPubMed
2.
go back to reference Singsen BH et al. Mixed connective tissue disease in childhood. A clinical and serologic survey. J Pediatr. 1977;90:893–900.CrossRefPubMed Singsen BH et al. Mixed connective tissue disease in childhood. A clinical and serologic survey. J Pediatr. 1977;90:893–900.CrossRefPubMed
3.
go back to reference Fraga A, Gudino J, Ramos-Niembro F, Aiarcon-Segovia D. Mixed connective tissue disease in childhood. Relationship Sjogren’s syndrome. Am J Dis Child. 1978;132:263–5.CrossRefPubMed Fraga A, Gudino J, Ramos-Niembro F, Aiarcon-Segovia D. Mixed connective tissue disease in childhood. Relationship Sjogren’s syndrome. Am J Dis Child. 1978;132:263–5.CrossRefPubMed
4.
go back to reference Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am. 2005;31:411–20.CrossRefPubMed Aringer M, Steiner G, Smolen JS. Does mixed connective tissue disease exist? Yes. Rheum Dis Clin North Am. 2005;31:411–20.CrossRefPubMed
5.
go back to reference Smolen JS, Steiner G. Mixed connective tissue disease: to be or not to be? Arthritis Rheum. 1998;41:768–77.CrossRefPubMed Smolen JS, Steiner G. Mixed connective tissue disease: to be or not to be? Arthritis Rheum. 1998;41:768–77.CrossRefPubMed
6.
go back to reference Burdt MA et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum. 1999;42:899–909.CrossRefPubMed Burdt MA et al. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum. 1999;42:899–909.CrossRefPubMed
7.
go back to reference Nimelstein SH, Brody S, McShane D, Holman HR. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore). 1980;59:239–48.CrossRef Nimelstein SH, Brody S, McShane D, Holman HR. Mixed connective tissue disease: a subsequent evaluation of the original 25 patients. Medicine (Baltimore). 1980;59:239–48.CrossRef
8.
go back to reference Gendi NS et al. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic follow up of 46 patients. Arthritis Rheum. 1995;38:259–66.CrossRefPubMed Gendi NS et al. HLA type as a predictor of mixed connective tissue disease differentiation. Ten-year clinical and immunogenetic follow up of 46 patients. Arthritis Rheum. 1995;38:259–66.CrossRefPubMed
9.
go back to reference Swanton J, Isenberg D. Mixed connective tissue disease: still crazy after all these years. Rheum Dis Clin North Am. 2005;31:421–36.CrossRefPubMed Swanton J, Isenberg D. Mixed connective tissue disease: still crazy after all these years. Rheum Dis Clin North Am. 2005;31:421–36.CrossRefPubMed
10.
go back to reference Black C, Isenberg DA. Mixed connective tissue disease—goodbye to all that. Br J Rheumatol. 1992;31:695–700.CrossRefPubMed Black C, Isenberg DA. Mixed connective tissue disease—goodbye to all that. Br J Rheumatol. 1992;31:695–700.CrossRefPubMed
11.
go back to reference Kahn MF, Appelboom T. In: Kahn MF, Peltier AP, Meyer O, editors. Les Maladies Systemiques. Paris: Flammarion; 1991. p. 545–56. Kahn MF, Appelboom T. In: Kahn MF, Peltier AP, Meyer O, editors. Les Maladies Systemiques. Paris: Flammarion; 1991. p. 545–56.
12.
go back to reference Sharp GC. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue diseases and anti-nuclear antibodies. Amsterdam: Excerpta Medica; 1987. p. 23–32. Sharp GC. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue diseases and anti-nuclear antibodies. Amsterdam: Excerpta Medica; 1987. p. 23–32.
13.
go back to reference Kasukawa R. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and anti-nuclear anti-bodies. Amsterdam: Exerpta Medica; 1987. p. 41–8. Kasukawa R. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and anti-nuclear anti-bodies. Amsterdam: Exerpta Medica; 1987. p. 41–8.
14.
go back to reference Alarcon-Segovia D, Villarreal M. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and anti-nuclear anti-bodies. Amsterdam: Excerpta Medica; 1987. p. 33–40. Alarcon-Segovia D, Villarreal M. In: Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and anti-nuclear anti-bodies. Amsterdam: Excerpta Medica; 1987. p. 33–40.
15.
go back to reference Amigues JM, Cantagrel A, Abbal M, Mazieres B. Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. J Rheumatol. 1996;23:2055–62.PubMed Amigues JM, Cantagrel A, Abbal M, Mazieres B. Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. J Rheumatol. 1996;23:2055–62.PubMed
16.
go back to reference Cappelli S et al. “To be or not to be,” ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum. 2012;41:589–98.CrossRefPubMed Cappelli S et al. “To be or not to be,” ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum. 2012;41:589–98.CrossRefPubMed
17.
go back to reference Lage LV, Caleiro MT, Carvalho JF. Proposed disease activity criteria for mixed connective tissue disease. Lupus. 2010;19:223–4.CrossRefPubMed Lage LV, Caleiro MT, Carvalho JF. Proposed disease activity criteria for mixed connective tissue disease. Lupus. 2010;19:223–4.CrossRefPubMed
18.
go back to reference Flam ST et al. The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases. Rheumatology (Oxford). 2015;54:528–35.CrossRef Flam ST et al. The HLA profiles of mixed connective tissue disease differ distinctly from the profiles of clinically related connective tissue diseases. Rheumatology (Oxford). 2015;54:528–35.CrossRef
19.
go back to reference Hoffman RW, Maldonado ME. Immune pathogenesis of mixed connective tissue disease: a short analytical review. Clin Immunol. 2008;128:8–17.CrossRefPubMed Hoffman RW, Maldonado ME. Immune pathogenesis of mixed connective tissue disease: a short analytical review. Clin Immunol. 2008;128:8–17.CrossRefPubMed
20.
go back to reference Keith MP et al. Anti-ribonucleoprotein antibodies mediate enhanced lung injury following mesenteric ischemia/reperfusion in Rag-1(−/−) mice. Autoimmunity. 2007;40:208–16.CrossRefPubMed Keith MP et al. Anti-ribonucleoprotein antibodies mediate enhanced lung injury following mesenteric ischemia/reperfusion in Rag-1(−/−) mice. Autoimmunity. 2007;40:208–16.CrossRefPubMed
21.
go back to reference Bodolay E et al. Anti-endothelial cell antibodies in mixed connective tissue disease: frequency and association with clinical symptoms. Clin Exp Rheumatol. 2004;22:409–15.PubMed Bodolay E et al. Anti-endothelial cell antibodies in mixed connective tissue disease: frequency and association with clinical symptoms. Clin Exp Rheumatol. 2004;22:409–15.PubMed
22.
go back to reference Petty R, Laxer R, Lindsey C, Wedderburn L. Textbook of pediatric rheumatology. Philadelphia: Elsevier; 2016. Petty R, Laxer R, Lindsey C, Wedderburn L. Textbook of pediatric rheumatology. Philadelphia: Elsevier; 2016.
23.•
go back to reference Gunnarsson R et al. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford). 2016;55:103–8. This study examines the serologic risk factors for ILD in MCTD and the authors identified the presence of anti-Ro52 as a potential risk factor for pulmonary fibrosis.CrossRef Gunnarsson R et al. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford). 2016;55:103–8. This study examines the serologic risk factors for ILD in MCTD and the authors identified the presence of anti-Ro52 as a potential risk factor for pulmonary fibrosis.CrossRef
24.
go back to reference van der Net J, Wissink B, van Royen A, Helders PJ, Takken T. Aerobic capacity and muscle strength in juvenile-onset mixed connective tissue disease (MCTD). Scand J Rheumatol. 2010;39:387–92.CrossRefPubMed van der Net J, Wissink B, van Royen A, Helders PJ, Takken T. Aerobic capacity and muscle strength in juvenile-onset mixed connective tissue disease (MCTD). Scand J Rheumatol. 2010;39:387–92.CrossRefPubMed
25.
go back to reference Kotajima L et al. Clinical features of patients with juvenile onset mixed connective tissue disease: analysis of data collected in a nationwide collaborative study in Japan. J Rheumatol. 1996;23:1088–94.PubMed Kotajima L et al. Clinical features of patients with juvenile onset mixed connective tissue disease: analysis of data collected in a nationwide collaborative study in Japan. J Rheumatol. 1996;23:1088–94.PubMed
26.
go back to reference Mier RJ et al. Pediatric-onset mixed connective tissue disease. Rheum Dis Clin North Am. 2005;31:483–96. vii.CrossRefPubMed Mier RJ et al. Pediatric-onset mixed connective tissue disease. Rheum Dis Clin North Am. 2005;31:483–96. vii.CrossRefPubMed
27.
go back to reference Sedej K et al. Autoimmune hepatitis as a presenting manifestation of mixed connective tissue disease in a child. Case report and review of the literature. Pediatr Rheumatol Online J. 2015;13:47.CrossRefPubMedPubMedCentral Sedej K et al. Autoimmune hepatitis as a presenting manifestation of mixed connective tissue disease in a child. Case report and review of the literature. Pediatr Rheumatol Online J. 2015;13:47.CrossRefPubMedPubMedCentral
28.
go back to reference Hajas A et al. Sensorineural hearing loss in patients with mixed connective tissue disease: immunological markers and cytokine levels. J Rheumatol. 2009;36:1930–6.CrossRefPubMed Hajas A et al. Sensorineural hearing loss in patients with mixed connective tissue disease: immunological markers and cytokine levels. J Rheumatol. 2009;36:1930–6.CrossRefPubMed
29.
go back to reference Aalokken TM et al. Chest abnormalities in juvenile-onset mixed connective tissue disease: assessment with high-resolution computed tomography and pulmonary function tests. Acta Radiol. 2009;50:430–6.CrossRefPubMed Aalokken TM et al. Chest abnormalities in juvenile-onset mixed connective tissue disease: assessment with high-resolution computed tomography and pulmonary function tests. Acta Radiol. 2009;50:430–6.CrossRefPubMed
30.
go back to reference Bodolay E et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford). 2005;44:656–61.CrossRef Bodolay E et al. Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology (Oxford). 2005;44:656–61.CrossRef
31.
go back to reference Sullivan WD et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore). 1984;63:92–107.CrossRef Sullivan WD et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore). 1984;63:92–107.CrossRef
32.
go back to reference Hetlevik, S., Flato, B., Rygg, M., Nordal, E. & Lilleby, V. Disease activity, disease damage and predictive factors in juvenile onset mixed connective tissue disease—a Norwegian nationwide study. Arthritis Rheum 67 (2015). Hetlevik, S., Flato, B., Rygg, M., Nordal, E. & Lilleby, V. Disease activity, disease damage and predictive factors in juvenile onset mixed connective tissue disease—a Norwegian nationwide study. Arthritis Rheum 67 (2015).
33.••
go back to reference Hof D et al. Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease. Arthritis Res Ther. 2005;7:R302–9. This recent study presents new outcome data for 48 patients with MCTD. The study presents the first data of potential predictors of damage and active disease in pediatric MCTD.CrossRefPubMedPubMedCentral Hof D et al. Autoantibodies specific for apoptotic U1-70K are superior serological markers for mixed connective tissue disease. Arthritis Res Ther. 2005;7:R302–9. This recent study presents new outcome data for 48 patients with MCTD. The study presents the first data of potential predictors of damage and active disease in pediatric MCTD.CrossRefPubMedPubMedCentral
34.
go back to reference Szodoray P et al. Distinct phenotypes in mixed connective tissue disease: subgroups and survival. Lupus. 2012;21:1412–22.CrossRefPubMed Szodoray P et al. Distinct phenotypes in mixed connective tissue disease: subgroups and survival. Lupus. 2012;21:1412–22.CrossRefPubMed
35.
go back to reference Tiddens HA et al. Juvenile-onset mixed connective tissue disease: longitudinal follow-up. J Pediatr. 1993;122:191–7.CrossRefPubMed Tiddens HA et al. Juvenile-onset mixed connective tissue disease: longitudinal follow-up. J Pediatr. 1993;122:191–7.CrossRefPubMed
36.
go back to reference Jais X et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008;58:521–31.CrossRefPubMed Jais X et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008;58:521–31.CrossRefPubMed
37.
go back to reference Rubin LJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903.CrossRefPubMed Rubin LJ et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903.CrossRefPubMed
38.
go back to reference Jovancevic B, Lindholm C, Pullerits R. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. Lupus. 2013;22:664–74.CrossRefPubMed Jovancevic B, Lindholm C, Pullerits R. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature. Lupus. 2013;22:664–74.CrossRefPubMed
39.
40.
go back to reference Tsai YY et al. Fifteen-year experience of pediatric-onset mixed connective tissue disease. Clin Rheumatol. 2010;29:53–8.CrossRefPubMed Tsai YY et al. Fifteen-year experience of pediatric-onset mixed connective tissue disease. Clin Rheumatol. 2010;29:53–8.CrossRefPubMed
41.
go back to reference Wallace CA et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63:929–36.CrossRef Wallace CA et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011;63:929–36.CrossRef
42.
go back to reference Knight A et al. Depression and anxiety and their association with healthcare utilization in pediatric lupus and mixed connective tissue disease patients: a cross-sectional study. Pediatr Rheumatol Online J. 2014;12:42.CrossRefPubMedPubMedCentral Knight A et al. Depression and anxiety and their association with healthcare utilization in pediatric lupus and mixed connective tissue disease patients: a cross-sectional study. Pediatr Rheumatol Online J. 2014;12:42.CrossRefPubMedPubMedCentral
43.
go back to reference Knight A et al. Identifying differences in risk factors for depression and anxiety in pediatric chronic disease: a matched cross-sectional study of youth with lupus/mixed connective tissue disease and their peers with diabetes. J Pediatr. 2015;167:1397–1403 e1.CrossRefPubMed Knight A et al. Identifying differences in risk factors for depression and anxiety in pediatric chronic disease: a matched cross-sectional study of youth with lupus/mixed connective tissue disease and their peers with diabetes. J Pediatr. 2015;167:1397–1403 e1.CrossRefPubMed
44.•
go back to reference Soltesz P et al. Endothelial cell markers reflecting endothelial cell dysfunction in patients with mixed connective tissue disease. Arthritis Res Ther. 2010;12:R78. This study highlights the prevalence and risk factors for mood disorders in MCTD as well as the lower rates of visits for mental health care.CrossRefPubMedPubMedCentral Soltesz P et al. Endothelial cell markers reflecting endothelial cell dysfunction in patients with mixed connective tissue disease. Arthritis Res Ther. 2010;12:R78. This study highlights the prevalence and risk factors for mood disorders in MCTD as well as the lower rates of visits for mental health care.CrossRefPubMedPubMedCentral
Metadata
Title
Pediatric Mixed Connective Tissue Disease
Authors
Roberta A. Berard
Ronald M. Laxer
Publication date
01-05-2016
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 5/2016
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-016-0576-x

Other articles of this Issue 5/2016

Current Rheumatology Reports 5/2016 Go to the issue

Infections and Arthritis (K Winthrop, Section Editor)

Fungal Infections and New Biologic Therapies

Complementary and Alternative Medicine (SL Kolasinski, Section Editor)

Is There a Role for Diet in the Therapy of Rheumatoid Arthritis?

Crystal Arthritis (MH Pillinger and SK Samuels, Section Editors)

The Role of ANK in Calcium Pyrophosphate Deposition Disease

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.